middle.news
Paradigm Biopharma Draws US$5M to Boost Global Knee Osteoarthritis Trial
7:04pm on Wednesday 18th of February, 2026 AEDT
•
Healthcare
Read Story
Paradigm Biopharma Draws US$5M to Boost Global Knee Osteoarthritis Trial
7:04pm on Wednesday 18th of February, 2026 AEDT
Key Points
US$5 million drawdown completed under Convertible Note Facility
Funding supports global Phase 3 trial of injectable pentosan polysulfate sodium
Trial recruitment approaching 50% milestone
Approximately US$10 million remains available for ongoing trial activities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX:PAR)
OPEN ARTICLE